@FierceBiotech: Take the poll: Has the biotech boom come to an end? More | Follow @FierceBiotech
@JohnCFierce: Sold out the Fierce London biotech conference, which is cool. Thank you, U.K. More | Follow @JohnCFierce
> The private equity owners of French drugmaker Ethypharm are considering selling the company, Bloomberg reports. News
> Biotech startup Oncoceutics raised an undisclosed sum in a Series A financing round, developing a novel treatment for cancer. More
> Valeant Pharmaceuticals ($VRX), under fire for its business model, is insisting its drug price increases are not as dramatic as is portrayed by media and lawmakers. Story
Medical Device News
@FierceMedDev: ICYMI yesterday: Baxter, Boston Sci back TVA in $15M round to ease hemodialysis vascular access. Report | Follow @FierceMedDev
@VarunSaxena2: #AdvaMed15: Director of @CMSGov says local coverage decisions are varying by locality. Not all geographies reimburse Dx tests the same way. | Follow @VarunSaxena2
@EmilyWFierce: Sold on diabetes tech, Joslin tests mobile app for Type 1 patients. FiercePharmaMarketing story | Follow @EmilyWFierce
> OptiNose raises up to $30M to get drug-device combo through FDA. Story
> Stratatech nabs $247M BARDA contract for skin tissue device. Article
Pharma News
@FiercePharma: Something's got to give in India's pharma policy contradictions. FiercePharmaAsia article | Follow @FiercePharma
@EricPFierce: AmerisourceBergen looks for compound interest with its $2.5B deal to buy PharMEDium. FiercePharmaManufacturing story | Follow @EricPFierce
@CarlyHFierce: ICYMI yesterday: Investors cheer as Arena forces out CEO and cofounder. More | Follow @CarlyHFierce
> U.K. cost gatekeeper says 'OK' to Merck's Keytruda for advanced skin cancer. Story
> Valeant hits back at price-hike critics amid national scrutiny. Article
> Two's company for PCSK9 meds as Praluent, Repatha both nab coverage from top PBM. More
Biotech Research News
> Rutgers researchers make headway with an HDAC inhibitor for Alzheimer's. More
> Alzheimer's: Investigators spotlight a pathway for amyloid beta clearance. Report
> Penn team shines a light on blood disorder. Item
> UCSC team reveals key structural component in telomerase enzyme. Story
> NIH researchers' new mouse model points to a gene therapy for eye disease. Article
Diagnostics News
> Myriad inks coverage deal for prostate cancer test. Item
> Invitae doubles genetic testing menu with cancer, neuromuscular offerings. Report
> Cancer Genetics makes strides in $14M deal for Response Genetics. More
> Invitae doubles genetic testing menu with cancer, neuromuscular offerings. Article
> Illumina expands in China with cancer Dx deal. Story
Pharma Marketing News
> Can Daklinza profit from a set of niche hep C uses? BMS may soon find out. Item
> Bristol-Myers shells out $14.7M in China bribery settlement. More
> British docs weigh in on pharma, and it's no better than most U.S. opinions. Report
> The data difference? Publicis adds data practice to sharpen healthcare media buying and planning. Story
> Glaxo OTC chief: When it comes to consumer health, pharma has the edge. Article